



www.MedChemExpress.com

Inhibitors, Screening Libraries, Proteins

Galectin

Galectins comprise a family of soluble β -galactoside binding proteins, which regulate key biological processes including cell growth, differentiation, apoptosis, and immune responses.

Sixteen galectin genes have been identified in animal kingdoms, 12 of which are expressed in humans. Galectins are usually classified into three groups based on their structure: (i) prototypical galectins (galectin-1 (Gal1), Gal2, Gal5, Gal7, Gal10, Gal11, Gal13, Gal14, and Gal15), characterized by a single CRD, which can act as monomers or form homodimers; (ii) the chimeric galectin Gal3 (the only member of this class), with a single CRD and a large amino-terminal domain that facilitates the formation of oligomers; (iii) the tandem repeat galectins, with two CRDs that are linked through a small peptide domain; this group includes Gal4, Gal6, Gal8, Gal9, and Gal12. Recently, Galectins have been implicated as major therapeutic determinants that confer sensitivity or resistance to a wide range of anticancer modalities including chemotherapy, radiotherapy, targeted therapies, antiangiogenic therapies, and immunotherapies.

Galectin Inhibitors

G3-C12

Cat. No.: HY-P1592

G3-C12 is a galectin-3 binding peptide, with K_d of 88 nM, and shows anticancer activity.

ANTPCGPYTHDCPVKR

Purity: 99.44%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

G3-C12 TFA

Cat. No.: HY-P1592A

G3-C12 (TFA) is a galectin-3 binding peptide, with K_d of 88 nM, and shows anticancer activity.


ANTPCGPYTHDCPVKR (TFA salt)

Purity: 99.45%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Galectin-3-IN-1

Cat. No.: HY-144312

Galectin-3-IN-1 (Compound 1) is a potent multivalent inhibitor of **galectin-3 (Gal-3)**. Galectin-3 participates in many cancer-related metabolic processes.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Galectin-3-IN-2

Cat. No.: HY-144313

Galectin-3-IN-2 (Compound 9) is a potent multivalent inhibitor of **galectin-3 (Gal-3; IC₅₀=8.3 μM)**. Galectin-3 participates in many cancer-related metabolic processes.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GB1107

Cat. No.: HY-114409

GB1107 is a potent, selective, orally active inhibitor of **Galectin-3 (Gal-3)** with a K_d of 37 nM for human Galectin-3. GB1107 reduces human and mouse lung adenocarcinoma growth and blocks metastasis in the syngeneic model.




Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

OTX008

(Calixarene 0118; PTX008)

Cat. No.: HY-19756

OTX008 is a selective inhibitor of **galectin-1**.




Purity: ≥98.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Thiodigalactoside

(TDG)

Cat. No.: HY-130208

Thiodigalactoside (TDG) is an orally active and potent **galectin (GAL)** inhibitor with K_d values of 24 μM, 49 μM for GAL1 and GAL3, respectively. Thiodigalactoside, a non-metabolizable disaccharide, has anti-inflammatory and anti-cancer activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 25 mg